EP3558308A1 — Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
Assigned to Novaliq GmbH · Expires 2019-10-30 · 7y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of tacrolimus and a liquid vehicle comprising at least one semifluorinated alkane for use in a method of treating an intraocular inflammatory eye disease.
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of tacrolimus and a liquid vehicle comprising at least one semifluorinated alkane for use in a method of treating an intraocular inflammatory eye disease.
Drugs covered by this patent
- Miebo (PERFLUOROHEXYLOCTANE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.